Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.58 |
| ▸ | CA2 | P00918 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 9/20 | 0.49 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14744565 | 0.80 | ALDH1A1 (0.66) | CA1CA2ALDH1A1NPSR1MAPT | |
| SCHEMBL4075954 | 0.76 | TSHR (0.54) | CA1CA2ALDH1A1 | |
| SCHEMBL9845455 | 0.75 | CA1 (0.70) | CA1CA2ALDH1A1NPSR1MAPT | |
| SCHEMBL11551946 | 0.75 | FFAR1 (0.63) | CA1CA2FFAR1KEAP1FFAR4 | |
| SCHEMBL30026591 | 0.74 | CA1 (0.58) | CA1CA2ALDH1A1NPSR1MAPT | |
| SCHEMBL69746 | 0.74 | FFAR1 (0.81) | CA1CA2FFAR1KEAP1LMNA | |
| SCHEMBL4964212 | 0.74 | CA2 (1.00) | CA1CA2ALDH1A1NPSR1MAPT | |
| SCHEMBL40250 | 0.74 | CA1 (0.68) | CA1CA2ALDH1A1NPSR1MAPT | |
| SCHEMBL1429021 | 0.74 | CA1 (0.68) | CA1CA2ALDH1A1NPSR1MAPT | |
| Lithium Ion SCHEMBL28445902 | 0.74 | CA1 (0.68) | CA1CA2ALDH1A1NPSR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1625112-B1 | NOVEL COMPOUNDS FOR TREATMENT OF OBESITY | HIGH POINT PHARMACEUTICALS LLC (US) | 2009-07-22 | — | — | EP | disclosed |
| US-20060128662-A1 | Novel compounds for treatment of obesity | NOVO NORDISK A/S (DK) | 2006-06-15 | — | — | US | disclosed |
| EP-1625112-A1 | NOVEL COMPOUNDS FOR TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2006-02-15 | — | — | EP | disclosed |
| WO-2004101505-A1 | NOVEL COMPOUNDS FOR TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128662-A1 | Novel compounds for treatment of obesity | GPR119, FABP4, HSD17B4 | CA1 4828/4885CA2 4544/4885ALDH1A1 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.